Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Meier, Juris J ^a   Bonadonna, Riccardo C ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ARTICLE; CELL DENSITY; CELL LOSS; CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; WESTERN BLOTTING;

BLOOD GLUCOSE; CELL COUNT; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GENETIC ASSOCIATION STUDIES; HUMANS; INCRETINS; INSULIN-SECRETING CELLS;

EID: 84890494543     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2008     Document Type: Article

References (75)

1. DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes melli-tus: a balanced overview. Diabetologia 1992;35:389-397
2. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984;74:1318-1328
3. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579-588
4. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006;91: 2906-2912
5. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985;4:110-125
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110
7. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4): 32-42
8. Maedler K. Beta cells in type 2 diabetes-a crucial contribution to pathogenesis. Diabetes Obes Metab 2008;10:408-420
9. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004;89:5535-5541
10. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003;52:726-733
11. Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 2006;41: 177-184
12. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glyce-mic durability of rosiglitazone, metfor-min, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
14. Meier JJ. Linking the genetics of type 2 diabetes with low birth weight: a role for prenatal islet maldevelopment? Diabetes 2009;58:1255-1256
15. Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008; 57:1584-1594
16. Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999;353:1789-1792
17. Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP. Effects of hem-ipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 1990;322:898-903
18. Menge BA, Schrader H, Breuer TG, et al. Metabolic consequences of a 50% partial pancreatectomy in humans. Diabetologia 2009;52:306-317
19. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-229
20. Toschi E, Camastra S, Sironi AM, et al. Effect of acute hyperglycemia on insulin secretion in humans. Diabetes 2002;51 (Suppl. 1):S130-S133
21. Laedtke T, Kjems L, Pørksen N, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 2000;279:E520-E528
22. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760
23. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009;52:1003-1012
24. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:5991-5997
25. Meier JJ, Breuer TG, Bonadonna RC, et al. Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 2012;55:1346-1354
26. Robertson RP, Lanz KJ, Sutherland DE, Seaquist ER. Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation 2002;73:736-741
27. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Pro-insulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 1995;44:173-179
28. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP. Hyper-proinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest 1996;97:455-460
29. Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006;55:1051-1056
30. Goodner CJ, Koerker DJ, Weigle DS, McCulloch DK. Decreased insulin-and glucagon-pulse amplitude accompanying beta-cell deficiency induced by strepto-zocin in baboons. Diabetes 1989;38:925-931
31. Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983;71: 1544-1553
32. Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted with advanced age. Diabetes 2009;58:1365-1372
33. Menge BA, Tannapfel A, Belyaev O, et al. Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes 2008;57:142-149
34. Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab 2008;295:E832-E841
35. Matveyenko AV, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 2012;61:2269-2279
36. Matveyenko AV, Veldhuis JD, Butler PC. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 2006;55:2347-2356
37. Menge BA, Gruber L, Jørgensen SM, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes 2011;60:2160-2168
38. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 2005;54: 1649-1656
39. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51:703-713
40. Pox C, Ritzel R, Busing M, et al. Combined pancreas and kidney transplantation in a lean type 2 diabetic patient. Effects on insulin secretion and sensitivity. Exp Clin Endocrinol Diabetes 2002;110:420-424
41. Ferrannini E. The stunned beta cell: a brief history. Cell Metab 2010;11:349-352
42. Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;93(Suppl. 1):S60-S65
43. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293:E1-E15
44. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
45. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C. Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 2007; 292:E54-E60
46. Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95: 5028-5036
47. Ohara-Imaizumi M, Nishiwaki C, Kikuta T, Nagai S, Nakamichi Y, Nagamatsu S. TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic beta-cells: different behaviour of granule motion between normal and Goto-Kakizaki diabetic rat beta-cells. Biochem J 2004;381:13-18
48. Jing X, Li DQ, Olofsson CS, et al. CaV2.3 calcium channels control second-phase insulin release. J Clin Invest 2005;115:146-154
49. Holness MJ, Hegazy S, Sugden MC. Signalling satiety and starvation to b-cell insulin secretion. Curr Diabetes Rev 2011;7:336-345
50. Pedersen MG, Toffolo GM, Cobelli C. Cellular modeling: insight into oral minimal models of insulin secretion. Am J Physiol Endocrinol Metab 2010;298: E597-E601
51. Pedersen MG, Dalla Man C, Cobelli C. Multiscale modeling of insulin secretion. IEEE Trans Biomed Eng 2011;58:3020-3023
52. Groop LC, Ratheiser K, Luzi L, et al. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study. Acta Diabetol 1991;28: 162-168
53. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin En-docrinol Metab 2005;90:493-500
54. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991;40:166-180
55. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
56. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-E1166
57. Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 2009; 32:866-872
58. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes 2005;54:1735-1743
59. Bonadonna RC, Stumvoll M, Fritsche A, et al. Altered homeostatic adaptation of first-and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function. Diabetes 2003; 52:470-480
60. Cali AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 2008;93:1767-1773
61. Cnop M, Hughes SJ, Igoillo-Esteve M, et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010;53:321-330
62. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab 2010;.95:E234-E239
63. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009;32: 514-520
64. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006;55:2025-2031
65. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Dia-betologia 2011;54:2506-2514
66. Malandrucco I, Pasqualetti P, Giordani I, et al. Very-low-calorie diet: a quick therapeutic tool to improve b cell function in morbidly obese patients with type 2 diabetes. Am J Clin Nutr 2012;95:609-613
67. Lehtovirta M, Kaprio J, Groop L, Trombetta M, Bonadonna RC. Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins. Diabetologia 2005;48:1604-1613
68. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics 2011;10:52-60
69. Ashcroft FM, Rorsman P. Diabetes melli-tus and the b cell: the last ten years. Cell 2012;148:1160-1171
70. Bonetti S, Trombetta M, Malerba G, et al. Variants and haplotypes of TCF7L2 are associated with b-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1. J Clin Endocrinol Metab 2011;96:E389-E93
71. Bonetti S, Trombetta M, Boselli ML, et al. Variants of GCKR affect both b-cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2. Diabetes Care 2011;34:1205-1210
72. Lyssenko V, Eliasson L, Kotova O, et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 2011;60: 2424-2433
73. Trombetta M, Bonetti S, Boselli M, et al. CACNA1E variants affect beta cell function in patients with newly diagnosed type 2 diabetes. The Verona newly diagnosed type 2diabetes study(VNDS)3. PLoS One 2012;7:e32755
74. Rosengren AH, Braun M, Mahdi T, et al. Reduced insulin exocytosis in human pancreatic b-cells with gene variants linked to type 2 diabetes. Diabetes 2012;61:1726-1733
75. Meier JJ, Menge BA, Breuer TG, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009;58: 1595-1603